It is dedicated to discovering and developing AAV-based therapies, by leveraging our proprietary AAV capsid technology platform and our proprietary scalable manufacturing platform across three modalities: gene replacement, vectorized antibody, and vectorized micro-RNA modulation. Lacerta Therapeutics is pleased to announce our new collaboration with UCB. This brings the potential to drive a fundamental change in how diseases...
It is dedicated to discovering and developing AAV-based therapies, by leveraging our proprietary AAV capsid technology platform and our proprietary scalable manufacturing platform across three modalities: gene replacement, vectorized antibody, and vectorized micro-RNA modulation. Lacerta Therapeutics is pleased to announce our new collaboration with UCB. This brings the potential to drive a fundamental change in how diseases are treated—by moving from treating symptoms, to disease modification, and eventually towards a cure.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.